Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EBV-specific autologous cytotoxic T lymphocytes
- Development stage
- Phase 1
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
EBV-specific autologous cytotoxic T lymphocytes (EBV-CTLs) are a form of adoptive immunotherapy where a patient's own T cells are collected, expanded ex vivo with specificity for Epstein-Barr virus (EBV) antigens, and then reinfused into the patient. These cells are designed to target and eliminate EBV-infected cells, including EBV-associated malignancies. The therapy works by reconstituting EBV-specific immune responses, allowing the expanded T cells to recognize and destroy cells expressing EBV antigens. EBV-CTLs can persist in patients for up to 3 years after infusion, traffic to tumor sites, and provide long-term immune surveillance against EBV-related diseases.
- Other names
- Autologous Epstein-Barr virus-specific cytotoxic T cellsAutologous EBV-specific T cells
02
Targets
EBNA1 (Epstein-Barr virus latency proteins)
Beyond the preview
Go deeper on EBV-specific autologous cytotoxic T lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EBV-specific autologous cytotoxic T lymphocytes.